Wolfe Research Eyes Cooper Companies Amid Activist Pressure

Key Highlights

Wolfe Research has identified The Cooper Companies (NYSE:COO) as a new investment opportunity, citing ongoing activist pressure as a key catalyst. The firm highlights the potential for value creation following a strategic review initiated after engagement from investors JANA and Browning West.

Situational Overview

Cooper Companies operates two distinct segments: the high-performing CooperVision, which holds a top position in the $11 billion global contact lens market, and the underperforming CooperSurgical division. According to Wolfe Research, recent acquisitions within CooperSurgical have negatively impacted profitability, overshadowing the strength of the core vision business.

Market Impact and Valuation

The company currently trades at a significant discount to its five-year average, at approximately 12.6 times its 2027 estimated price-to-earnings ratio. Wolfe Research has set a fair value target of $90 per share, suggesting considerable upside. The strategic review remains a pivotal factor for future performance and investor sentiment.

Summary

Investors are closely monitoring the outcome of Cooper's strategic review, which could unlock value by addressing the performance gap between its two main divisions. The activist involvement is expected to maintain pressure on management to improve shareholder returns.

FAQ

Q: Why is Wolfe Research highlighting Cooper Companies?
A: Due to activist pressure forcing a strategic review and the stock trading at a discount despite its strong CooperVision segment.

Q: What is the primary challenge for Cooper Companies?
A: The CooperSurgical division is underperforming and negatively impacting overall profitability, which overshadows its successful contact lens business.

Source: Investing.com